Vestmark Advisory Solutions, Inc. Adaptimmune Therapeutics PLC Transaction History
Vestmark Advisory Solutions, Inc.
- $2.16 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding ADAP
# of Institutions
84Shares Held
160MCall Options Held
42.8KPut Options Held
42.1K-
Matrix Capital Management Company, LP Waltham, MA39MShares$40.9 Million0.57% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$28.8 Million1.23% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$17.9 Million1.89% of portfolio
-
Baillie Gifford & CO15.9MShares$16.7 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY10.8MShares$11.3 Million0.22% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $172M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...